ArticleESMO gastrointestinal oncology2026
TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trophoblast cell surface antigen 2 (TROP2) is frequently expressed in solid tumors, including gastric cancer (GC) and gastroesophageal junction cancer (GEJC), but its distribution and clinical relevance remain unclear. Patients and methods: We analyzed patients with GC/GEJC who underwent prospective multibiomarker testing. TROP2 expression was assessed by immunohistochemistry using multiple cut-offs and associations with clinicopathological features, biomarkers, and outcomes were evaluated. Results: Among 272 patients (169 with metastatic cancer), TROP2 expression was observed in 87%, 79%, and 62% at ≥25%, ≥50%, and ≥75% cut-offs, respectively. Higher cut-offs were associated with higher proportions of male patients, gastroesophageal junction tumors, intestinal-type histology, and liver metastasis. Among patients with TROP2-high tumors (>75% positivity), positivity rates in the full cohort were 17.8% for human epidermal growth factor receptor 2, 50.9% for claudin 18.2, 4.7% for deficient mismatch repair, and 30.2% for a programmed death-ligand 1 combined positive score >10; in the metastatic cohort, the corresponding rates were 18.6%, 48.0%, 5.9%, and 35.3%, respectively. Overall, 38.8% of TROP2-high patients in the full cohort and 31.3% in the metastatic cohort were negative for all four biomarkers. TROP2 expression was not associated with treatment outcomes for first-line platinum-based doublet chemotherapy or second-line taxane-based chemotherapy. Conclusions: TROP2 is widely expressed in GC/GEJC irrespective of stage. Higher expression thresholds delineate distinct clinicopathological features without prognostic impact. Its broad prevalence extends to patients lacking actionable biomarkers, supporting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.